Cat. No.: HY-N0237

Atractyloside A

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Atractyloside A is an orally active inhibitor of the TLR4/MyD88/NF-κB signaling pathway and also an opener of the mitochondrial permeability transition pore (MPTP). Atractyloside A interferes with the activation of the TLR4/MyD88/NF-κB pathway, thereby inhibiting intestinal inflammatory responses. Atractyloside A reverses mucin synthesis impairment, improves intestinal barrier integrity, and restores homeostasis by altering the composition of the gut microbiota. Atractyloside A can be used in studies related to spleen deficiency diarrhea and myocardial injury.

For research use only. We do not sell to patients.

Purity: 98.11%
CAS No.: 126054-77-1
Formula: C₂₁H₃₆O₁₀
Molecular Weight:448.50

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Atractyloside A Chemical Structure

CAS No.: 126054-77-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Toll-like Receptor (TLR) Isoforms :

All NF-κB Isoforms :

All Interleukin Related Isoforms :

In Vitro

Atractyloside A (10 μM; 12 h) abolishes the TRAP1-mediated protective effects on H9C2 cells in acidic medium (pH 6.5) by increasing MPTP opening, promoting apoptosis, reducing cell viability, impairing mitochondrial function, and disrupting mitochondrial ultrastructure^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atractyloside-A (5-10 mg/kg; p.o.; daily; for 7 consecutive days) exerts a dose-dependent therapeutic effect on spleen-deficiency diarrhea (SDD) in male ICR mice^[2].
Atractyloside-A (10 mg/kg; p.o.; once daily; for 7 consecutive days) fails to alleviate SDD symptoms in male ICR mice with depleted gut microbiota, indicating that gut microbiota is essential for its therapeutic activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice (male, 3 weeks old)^[2]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Increased body weight gain compared to SDD mice; reduced fecal moisture, diarrhea scores, and diarrhea index; partially restored colon morphological structure, reduced colonic inflammatory cell infiltration, and increased goblet cell and MUC2 levels; upregulated colon AQP3, AQP4, and AQP8 expression; increased colonic ZO-1 and occludin tight junction protein levels; downregulated colonic pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and serum DAO and 5-HT levels; upregulated colonic anti-inflammatory cytokine IL-10 levels; downregulated colonic TLR4, MyD88, p-IKK-α, p-IκB-α, and p-p65 protein expression; shifted intestinal flora composition toward the control group, including increased Lactobacillus abundance.
Produced greater improvements than the 5 mg/kg dose, including significantly higher body weight gain from day 2 onward; significantly reduced fecal moisture, diarrhea scores, and diarrhea index; significantly increased colon length (exceeding control levels); fully restored colon morphological structure with reduced inflammation, increased goblet cell and MUC2 levels; significantly upregulated colon AQP3, AQP4, and AQP8 expression; significantly increased colonic ZO-1 and occludin levels; significantly downregulated colonic TNF-α, IL-1β, IL-6, serum DAO, and 5-HT levels; significantly upregulated colonic IL-10 levels; significantly downregulated colonic TNF-α, TLR4, MyD88, p-IKK-α, p-IκB-α, and p-p65 protein expression; normalized intestinal flora clustering to match the control group, with significant increases in Lactobacillus, Bacteroides, Ruminococcus, and Intestinimonas abundances.

Chemical Information

CAS No. 126054-77-1
Appearance Solid
Molecular Weight 448.50
Formula C₂₁H₃₆O₁₀
Color White to light yellow
SMILES

O=C1[C@@](C)(O)[C@]2([H])C[C@H](C(C)(O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C)CC[C@@](CO)(O)[C@@]2([H])C1
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Plants
- Compositae
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All Cell Proliferation/Viability AssayIFWBHistological Imaging/StainingFlow Cytometry

Sort by:

Journal Impact Factor

Int J Mol Med

TRAP1 attenuates H9C2 myocardial cell injury induced by extracellular acidification via the inhibition of MPTP opening. [Abstract]

2020 Aug;46(2):663-674. PMID: 32626957
Front Microbiol

Antiviral effects of Atractyloside A on the influenza B virus (Victoria strain) infection. [Abstract]

2023 Jan 10:13:1067725. PMID: 36704555

Atractyloside A purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2023 Jan 10:13:1067725. [Abstract]

Cell viability of Atractyloside A (1, 5, 10, 20, 30, 40, 50, 80, 100 μM) on A549 and MDCK.

Atractyloside A purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2023 Jan 10:13:1067725. [Abstract]

Immunofluorescence analysis of the expression of IBV nucleoprotein after infection treated with various concentrations of Atractyloside A (AA) for 24 h.

Atractyloside A purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2023 Jan 10:13:1067725. [Abstract]

Western blot analysis of RIG-I pathway proteins after IBV infection in Atractyloside A (20, 30, 40 μM) treatment groups with different drug concentrations.

Atractyloside A purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2023 Jan 10:13:1067725. [Abstract]

H&E analysis of lung tissue after infection treated with Atractyloside A (AA) (10, 30 mg/kg, p.o.).

Atractyloside A purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2023 Jan 10:13:1067725. [Abstract]

Effect of Atractyloside A treatment on the polarization levels of macrophages in vitro. Flow cytometry was performed to analyze the proportions of bone marrow-derived macrophages (BMMs).
Bull Exp Biol Med

The Role of NO Synthase, MPT pore, and Protein Kinase A in the Cardioprotective Effect of the Opioid Receptor Agonist Deltorphin II. [Abstract]

2023 Apr;174(6):745-748. PMID: 37160797

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (111.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2297 mL

11.1483 mL

22.2965 mL

5 mM

0.4459 mL

2.2297 mL

4.4593 mL

10 mM

0.2230 mL

1.1148 mL

2.2297 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang L, et al. TRAP1 attenuates H9C2 myocardial cell injury induced by extracellular acidification via the inhibition of MPTP opening. Int J Mol Med. 2020;46(2):663-674. [Content Brief]

[2]. Xu J, et al. Atractyloside-A ameliorates spleen deficiency diarrhea by interfering with TLR4/MyD88/NF-κB signaling activation and regulating intestinal flora homeostasis. Int Immunopharmacol. 2022;107:108679. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2297 mL	11.1483 mL	22.2965 mL	55.7414 mL
	5 mM	0.4459 mL	2.2297 mL	4.4593 mL	11.1483 mL
	10 mM	0.2230 mL	1.1148 mL	2.2297 mL	5.5741 mL
	15 mM	0.1486 mL	0.7432 mL	1.4864 mL	3.7161 mL
	20 mM	0.1115 mL	0.5574 mL	1.1148 mL	2.7871 mL
	25 mM	0.0892 mL	0.4459 mL	0.8919 mL	2.2297 mL
	30 mM	0.0743 mL	0.3716 mL	0.7432 mL	1.8580 mL
	40 mM	0.0557 mL	0.2787 mL	0.5574 mL	1.3935 mL
	50 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL
	60 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9290 mL
	80 mM	0.0279 mL	0.1394 mL	0.2787 mL	0.6968 mL
	100 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5574 mL

Atractyloside A

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Atractyloside A

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Atractyloside A

All Toll-like Receptor (TLR) Isoforms

All NF-κB Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Atractyloside A Related Classifications

Cat. No.: HY-N0237